Opsonization

How opsonization works

The Greek opson means "relish" or "seasoning that makes food appetizing." The metaphor is exact. Phagocytes — neutrophils, macrophages, dendritic cells — are picky eaters. A bare microbial surface, especially one with a polysaccharide capsule, doesn't look appetizing to them; their pattern-recognition receptors get little purchase, and engulfment is sluggish or absent. Opsonins are the seasoning: molecular tags that decorate the surface and present a uniform, high-affinity handle for the phagocyte's receptors. The phagocyte recognizes the seasoning, not the food itself.

Two opsonins do most of the work. IgG binds antigen on the pathogen with its Fab arms, leaving the Fc tail projecting outward to engage phagocyte Fcγ receptors. C3b — the major activated fragment of complement — is deposited covalently on the surface via its thioester bond, and binds complement receptors CR1, CR3, and CR4 on phagocytes. Each opsonin is multivalent on a typical bacterium: thousands of IgG molecules and tens of thousands of C3b molecules can cover a single coccus.

The engulfment itself is a stereotyped sequence. Receptor clustering on the phagocyte side activates ITAM-Syk signaling (for FcγR) or Vav-Rac signaling (for CR3), which drives actin polymerization beneath the contact point. The membrane extends pseudopods that wrap around the opsonized particle in a "zipper" model, with each progressive receptor engagement triggering the next bit of actin to extend. Within a minute the membrane closes over the top, fusing to form a phagosome around the engulfed particle. The phagosome then matures — acidifies, fuses with lysosomes, accumulates NADPH oxidase products — and digests the contents. The whole process from contact to phagosome formation takes 1-2 minutes for a well-opsonized pneumococcus, vs hours or never for the same bacterium uncoated.

The thousand-fold acceleration comes from receptor density and binding kinetics. A single FcγR-Fc bond has affinity around 10⁷ M⁻¹ — modest. But two thousand bonds in the contact patch give effective avidity of ~10²⁰ M⁻¹ — essentially irreversible. Bare surfaces engage only sparse pattern-recognition receptors with much lower density. Opsonization swaps a low-density specific surface for a high-density generic Fc/C3b coating that phagocytes are evolutionarily tuned to grab.

Worked clinical example: pneumococcal clearance in a vaccinated vs unvaccinated host

Streptococcus pneumoniae enters the lower respiratory tract of two patients. The bacterium has a polysaccharide capsule — its primary virulence factor. The capsule blocks alveolar macrophage TLRs from engaging cell-wall lipoteichoic acid, and it sterically interferes with direct phagocyte contact. Bare pneumococcus is engulfed at rates around 10⁻³ per phagocyte per second — essentially negligible at the bacterial densities seen in early infection.

In the unvaccinated patient: there are no anti-capsule antibodies. Complement activation begins through the alternative pathway as factor B and factor D bind the bacterial surface, but only sparsely — pneumococcal surface proteins like factor H binding protein actively recruit complement regulators that strip C3b. Within an hour, perhaps 100 C3b molecules per bacterium have stuck — enough for slow CR3-mediated uptake but not enough to keep ahead of bacterial replication (doubling time ~30 minutes for pneumococcus in lung). Bacterial density rises, bacteremia ensues, and within 24-48 hours the patient may be septic with mortality 10-25%.

In the vaccinated patient (PCV13 or PPSV23 conjugate vaccine): pre-existing anti-capsular IgG specific for the colonizing serotype is present at serum concentrations of ~1-10 μg/mL. Within minutes of pneumococcal exposure in the lung, IgG coats the capsule — perhaps 5000 IgG molecules per bacterium. The classical complement pathway activates: each IgG-bound C1q complex cleaves C4 and C2, generating classical C3 convertase, depositing 10⁴-10⁵ C3b per bacterium within an hour. Alveolar macrophages now engage opsonized pneumococcus at ~1 per phagocyte per minute. The patient may have a transient cough, perhaps a fever, but rarely progresses to invasive disease. Vaccinated asplenic adults still receive lifelong penicillin prophylaxis because the spleen's clearance role can't be fully replaced.

Numerically: vaccine-induced IgG opsonization plus classical pathway C3b deposition increases phagocytic uptake roughly 1000-fold over the unvaccinated host, which is enough to outpace bacterial replication and prevent invasive disease.

Opsonins compared

Opsonin	Source	Phagocyte receptor	Speed	Specificity
IgG1, IgG3	Plasma cells (adaptive)	FcγRI, FcγRIIa, FcγRIIIa	Days to develop; rapid recall	Antigen-specific
IgG2	Anti-polysaccharide B cells	FcγRIIa (allele-dependent)	Slow primary, faster recall	Polysaccharide capsules
IgA1, IgA2 (secretory)	Mucosal B cells	FcαRI on macrophages	Local mucosal	Antigen-specific
C3b	Complement (alt, classical, lectin)	CR1 (CD35)	Minutes	Broad (alt) or antibody-directed (classical)
iC3b	C3b processed by factor I	CR3 (CD11b/CD18), CR4	Minutes	Same as C3b
Mannose-binding lectin	Liver (acute phase)	Indirect via lectin pathway → C3b	Hours to days induction	Mannose-rich surfaces
C-reactive protein	Liver (acute phase, IL-6 driven)	FcγRIIa indirectly + classical pathway via C1q	Hours (rises 100-1000× in infection)	Phosphocholine on damaged cells/pneumococcus

The redundancy is functional. C-reactive protein and mannose-binding lectin handle novel pathogens with no pre-existing antibody; alternative pathway C3b handles surfaces lacking sialic acid; IgG handles anything for which the host has prior immunity. In practice, healthy hosts engage two or three opsonins simultaneously on a typical infection.

Variants and molecular details

• FcγR isotype map. FcγRI (CD64) is high-affinity, monomeric IgG-binding, induced by IFN-γ. FcγRIIa (CD32a) is medium affinity, polymorphic — H131 and R131 variants differ in IgG2 binding. FcγRIIIa (CD16a) on NK cells drives ADCC; allotype 158V binds IgG1 more strongly than 158F, and patients with V/V genotype respond better to rituximab. FcγRIIb is the only inhibitory Fc receptor (ITIM-bearing) and dampens B cell activation.
• Antibody-dependent cellular cytotoxicity (ADCC). NK cells engage IgG-coated targets via FcγRIIIa and release perforin/granzyme, killing the target. Same opsonization principle but cytotoxicity instead of phagocytosis. Therapeutic monoclonals (rituximab, trastuzumab) work partly through ADCC.
• Antibody-dependent cellular phagocytosis (ADCP). Macrophages eating IgG-coated targets. Increasingly recognized as a major mechanism of monoclonal antibody therapy in solid tumors and hematologic malignancies.
• Frustrated phagocytosis. When a target is too large to engulf (immune complexes deposited in tissue, large parasites), receptor engagement still triggers exocytosis of granule contents — degranulation onto the target. Mechanism behind type III hypersensitivity tissue damage.
• Antibody-dependent enhancement (ADE). Some viruses (dengue, certain coronaviruses experimentally) can exploit Fc receptor-mediated entry — opsonization actually facilitates infection rather than clearance. Important in dengue's second-infection severity and a concern in vaccine design.
• Pathogen evasion. Staphylococcus aureus protein A binds IgG Fc backwards, presenting Fab to the bacterium and Fc to nowhere — blocking opsonization. Streptococcal M protein blocks alternative pathway C3b deposition. HIV gp41 has Fc-binding properties. Each is a target for vaccine design.

Disease relevance

• Encapsulated bacterial infections. Pneumococcus, Hib, meningococcus, group B strep, Klebsiella — all require opsonization for clearance because their capsules block direct phagocyte recognition. Asplenic patients (sickle cell disease, surgical splenectomy, congenital absence), complement-deficient patients (C3, factor B, properdin, MBL), and antibody-deficient patients (X-linked agammaglobulinemia, CVID, hyper-IgM, IgG subclass deficiency) have markedly increased risk of invasive pneumococcal disease.
• Pneumococcal vaccines. PCV13 and PCV20 conjugate vaccines, PPSV23 polysaccharide vaccine — induce anti-capsular IgG that opsonizes pneumococcus. Conjugate (carrier-linked) versions work in children <2 yrs by recruiting T-cell help; pure polysaccharide vaccines work poorly in this age group.
• Meningococcal disease. Late complement deficiencies (C5-C9) cause recurrent Neisseria infections because lytic terminal complement is more important than opsonization for Neisseria. Early complement defects (C3) cause encapsulated bacterial infections including Neisseria via failed opsonization.
• Therapeutic monoclonal antibodies. Rituximab (anti-CD20) opsonizes B cells for macrophage destruction in lymphoma, rheumatoid arthritis, multiple sclerosis. Trastuzumab opsonizes HER2-positive breast cancer cells. Daratumumab opsonizes CD38+ plasma cells in myeloma. All depend on FcγR-mediated phagocytosis and ADCC by host effector cells.
• Autoimmune hemolytic anemia. IgG opsonization of red blood cells by autoantibodies leads to splenic macrophage phagocytosis. Coombs (direct antiglobulin) test detects red-cell-bound IgG and/or C3. Splenectomy can be therapeutic by removing the major opsonized-RBC clearance site.
• Immune thrombocytopenia. Antibody opsonization of platelets drives splenic destruction. IVIG works partly by FcγR blockade — flooding the system with non-specific IgG that competes for FcγR with opsonized platelets.
• Hemolytic disease of the fetus and newborn. Maternal IgG anti-Rh crosses placenta, opsonizes fetal red cells, splenic macrophages clear them. Anti-D Ig prophylaxis (RhoGAM) clears Rh+ fetal cells from maternal circulation before sensitization.

Common pitfalls and misconceptions

• "Antibodies kill bacteria directly." Mostly they don't. Their effector function is opsonization (Fc → phagocyte), complement activation (Fc → C1q → cascade), and neutralization (blocking pathogen function). Direct bactericidal activity by antibody alone is rare.
• "IgM doesn't opsonize." IgM is a pentamer and can fix complement very effectively via C1q binding — its opsonization happens indirectly through C3b deposition rather than direct Fc receptor engagement. Fcμ receptors exist but are minor.
• "Complement deficiency is rare and unimportant." Late complement deficiencies (C5-C9, properdin) are rare but devastating — recurrent meningococcal disease. C2 deficiency is the most common complete complement deficiency and predisposes to SLE-like disease and encapsulated infections.
• "More opsonization is always better." Excessive opsonization can cause type II hypersensitivity (autoimmune cytopenias), immune complex disease, and antibody-dependent enhancement in some viral infections. Therapeutic monoclonals can cause infusion reactions through massive Fc engagement.
• "Opsonization is the whole story." Phagocytes also recognize pathogens through pattern-recognition receptors (TLRs, NLRs, dectin-1) and scavenger receptors. Opsonization complements these mechanisms and dominates for encapsulated organisms, but isn't the only route.
• "All IgG subclasses opsonize equally." IgG1 and IgG3 are the best opsonins because they engage FcγRI strongly and fix complement well. IgG2 opsonizes polysaccharides specifically. IgG4 is poor at both — almost inert from an effector standpoint, which is why it's the favored class in chronic allergen exposure and allergen immunotherapy.

Therapeutic applications

• Therapeutic monoclonal antibodies. The largest growing drug class. Rituximab, ofatumumab, obinutuzumab (anti-CD20); trastuzumab, pertuzumab (anti-HER2); cetuximab, panitumumab (anti-EGFR); daratumumab (anti-CD38); brentuximab vedotin (anti-CD30 ADC). All depend on FcγR-mediated phagocytosis, ADCC, or both. Glycoengineering (afucosylation) boosts FcγRIIIa binding; "Fc silencing" mutations reduce effector function when desired.
• IVIG. Intravenous immunoglobulin for primary antibody deficiencies (replacement) and autoimmune conditions (immunomodulation). High-dose IVIG saturates FcγR, prevents pathogenic opsonization, and is first-line for ITP, Kawasaki, Guillain-Barré, and many others.
• Anti-Rh prophylaxis. RhoGAM in Rh-negative mothers carrying Rh-positive fetuses — opsonizes fetal RBCs in maternal circulation for splenic clearance before sensitizing the mother. Single antenatal dose at ~28 weeks plus postnatal dose has nearly eliminated Rh hemolytic disease in developed countries.
• Vaccines targeting opsonization. Conjugate vaccines for pneumococcus (PCV13, PCV20), Hib, meningococcus C, and group B strep induce protective anti-capsular IgG. Vaccine efficacy is correlated with serum opsonophagocytic activity, measured in vitro by killing of bacteria in the presence of immune serum and phagocytes.
• Complement modulation. Eculizumab (anti-C5) blocks terminal complement in paroxysmal nocturnal hemoglobinuria, atypical HUS, myasthenia gravis. Doesn't affect opsonization-stage C3 but blocks terminal lysis.
• FcγR-engineered antibodies. "Effector-enhanced" mAbs (afucosylated, glycoengineered, or with Fc mutations like S239D/I332E) bind FcγRIIIa more avidly, boosting ADCC and ADCP. Approved examples: mogamulizumab (defucosylated anti-CCR4), obinutuzumab (glycoengineered anti-CD20).